JANX Janux Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why JANX matters now
Janux Therapeutics, Inc. (JANX) is a US stock in Healthcare. The latest InvestLog snapshot shows $18.60 with +6.96% on the session and $1.13B in market capitalization; recent performance reads 1-month +2.97% and YTD +3.04%.
The latest financial table shown here is Q1 2026, with revenue of $3.7M, net income of $-24.4M, and EPS of $-0.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.1%.
The latest indexable market news headline is "Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More" from 247 Wallst.
Additional event context on this page matters because analyst consensus is Buy with a median target of $22.00; recent insider activity includes Barrett Ronald W filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.95
P/S
40.12
EV/EBITDA
-7.44
DCF Value
$-3.12
FCF Yield
-9.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
54.1%
Operating Margin
-726.3%
Net Margin
-529.7%
ROE
-11.8%
ROA
-11.1%
ROIC
-16.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $3.7M | $-24.4M | $-0.39 |
| Q4 2025 | $7.9M | $-31.9M | $-0.51 |
| FY 2025 | $10.0M | $-113.6M | $-1.83 |
| Q3 2025 | $10.0M | $-24.3M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.40
Target (Median)
$22.00
Target Range
$14.00 - $36.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.52
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.